Written Informed Consent Act
- Sponsor
- Rep. Bilirakis, Gus M. [R-FL-12]
- Committees
- Veterans' Affairs Committee (primary)
- Last action
- Dec 19, 2025
Bottom line
This bill aims to enhance patient autonomy and safety within the VA healthcare system by requiring explicit written informed consent for a broader range of commonly prescribed psychiatric and pain medications.
What it actually does
This bill mandates that the Department of Veterans Affairs (VA) expand its existing informed consent directive for long-term opioid therapy to include antipsychotics, stimulants, antidepressants, anxiolytics, and narcotics. This means veterans would be required to provide written informed consent before receiving these types of medications, ensuring they understand the risks, benefits, and alternatives.
Proponents argue
Supporters argue this bill empowers veterans by ensuring they receive comprehensive information about potentially powerful medications, allowing them to make truly informed decisions about their treatment. They contend it protects veterans from potential over-prescription or adverse effects by formalizing the consent process, especially for drugs with significant side effects or dependency risks.
Opponents contend
Opponents might argue that expanding the written informed consent requirement to such a broad range of medications could create unnecessary bureaucratic hurdles, slow down access to essential care, and increase administrative burden on VA clinicians. They might also suggest that existing verbal consent processes and doctor-patient discussions are sufficient, and a written mandate could be perceived as paternalistic or distrustful of medical professionals.
The bill is extremely short and can be read and understood quickly, making it highly accessible for public review.
Section 2
Expansion of Informed Consent Requirements for Certain Medications
This section directs the Secretary of Veterans Affairs to update an existing Veterans Health Administration (VHA) directive, VHA Directive 1005, which currently requires informed consent for long-term opioid therapy. The update will expand this requirement to include five additional categories of medications: antipsychotics, stimulants, antidepressants, anxiolytics, and narcotics. This means that for these medications, VA healthcare providers would need to obtain written informed consent from veterans, detailing the risks, benefits, and alternatives, similar to the process for long-term opioids.
Supporters argue
Supporters argue that requiring written informed consent for these powerful medications ensures veterans fully understand the potential side effects, risks of dependency, and available alternatives, thereby protecting their health and promoting patient-centered care. They believe it addresses concerns about over-prescription and ensures veterans are active participants in their treatment plans.
Critics contend
Critics might contend that while the intent is good, the practical implementation could create significant delays in care, especially for veterans in acute distress or those requiring immediate medication adjustments. They may argue that existing verbal consent and patient education are sufficient, and adding a written mandate for such a broad range of common medications could be an unnecessary bureaucratic hurdle that strains VA resources and clinician time.
Tradeoffs
The bill balances the desire to enhance patient autonomy and safety through informed consent against the potential for increased administrative burden on healthcare providers and possible delays in access to necessary medications within the VA system.